PROFILE |
 |
Oxford GlycoSciences uses the separation, identification, and characterization of proteins (proteomics) to develop new pharmaceuticals. Using proteomics, the firm identifies proteins that may correspond with certain diseases. The firm's lead drug candidate, Vevesca, is waiting FDA approval as a therapy for Gaucher's disease. The company also has antifungal and anticancer drugs in development. Oxford GlycoSciences has filed patents covering more than 1,500 disease-specific proteins that may have applications for such ailments as rheumatoid arthritis, breast cancer, and Alzheimer's disease. Its partners include Bayer, GlaxoSmithKline, Pfizer, Packard BioScience, and Applera.
COMPETITION |
 |
Genzyme Corporation (GENZ)
Large Scale Biology Corporation (LSBC)
Scios Inc. (SCIO)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 13.30
1-Yr. Sales Growth: (5.2)%
Employees: 186
Revenue per employee: $71,505.38
KEY PEOPLE |
 |
Michael L. Kranda
CEO
Stephen B. Parker
CFO
CONTACT INFO |
 |
The Forum, 86 Milton Park
Abingdon Oxfordshire OX14 4RY, United Kingdom
Phone: 44-1235-208-000
Fax: 44-1235-208-020
Online: Web Site
|